Citius Pharmaceuticals, INC

Citius Oncology announces a significant 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR, alongside near-universal payer coverage and expanding formulary approvals.

Citius Oncology announced positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, showing durable responses and manageable tolerability.

Citius Pharmaceuticals reports $5.6 million in LYMPHIR net revenue for the first half of fiscal 2026 and secures $41.5 million in total new financing.

Citius Pharmaceuticals and its subsidiary, Citius Oncology, have amended a $3.8M promissory note to align with new senior debt obligations and introduce a conversion feature.

Citius Oncology announces the initial shipment of its oncology drug LYMPHIR to Europe, expanding international patient access through regional distribution partners and Named Patient Programs.

Citius Pharmaceuticals has raised $5 million in gross proceeds through a registered direct offering and concurrent private placement to support the commercialization of LYMPHIR.

Citius Pharmaceuticals reports its first commercial revenue from LYMPHIR, alongside a significant net loss and a 'going concern' warning, necessitating further capital raises.

Citius Pharmaceuticals reports progress on LYMPHIR commercialization and Mino-Lok development, but faces ongoing significant losses and a need for substantial additional capital.

Citius Pharmaceuticals reports a net loss of $11.5 million for the three months ended March 31, 2025, and acknowledges substantial doubt about its ability to continue as a going concern.

Citius Pharmaceuticals reports a net loss for Q1 2025 and expresses concerns about its ability to continue as a going concern without additional funding.

Citius Pharmaceuticals announced its Q3 2024 results, highlighted by the FDA approval of LYMPHIR and the completion of the Citius Oncology spin-off.

Citius Pharmaceuticals reported a net loss of $17.8 million for the six months ended March 31, 2024, and faces uncertainty about its ability to continue as a going concern despite a recent capital raise and the resubmission of its BLA for LYMPHIR.

Citius Pharmaceuticals, Inc. filed an amendment to its annual report to include detailed information on executive compensation, corporate governance, and related party transactions for the fiscal year ended September 30, 2025.

Citius Pharmaceuticals, Inc. reports a net loss of $39.7 million for fiscal year 2025, with its subsidiary Citius Oncology launching LYMPHIR amidst ongoing funding needs and product development.

Citius Pharmaceuticals files an amendment to its annual report on Form 10-K to include updated executive certifications and a compensation recovery policy.

Citius Pharmaceuticals' annual 10-K filing outlines the company's capital structure, recent reverse stock split, progress with LYMPHIR, and ongoing development of other product candidates, while also highlighting financial risks and future funding needs.

Citius Pharmaceuticals CEO Leonard L. Mazur extended the expiration dates of two tranches of warrants and updated his beneficial ownership of common stock and stock options.

Citius Pharmaceuticals' Vice Chairman Myron Z. Holubiak reported warrant term extensions and detailed various stock option holdings in a recent SEC filing.

Director Carol Webb of Citius Pharmaceuticals acquired 125,000 shares through stock options, as detailed in a recent SEC Form 4 filing.

A Citius Pharmaceuticals director, Robert Joseph Smith, has acquired stock options for 125,000 shares at an exercise price of $0.38 and 75,000 shares at an exercise price of $0.69.

Citius Pharmaceuticals' Chief Financial Officer, Jaime Bartushak, reported the grant of 350,000 stock options and existing holdings of various other stock options.

Citius Pharmaceuticals CEO Leonard Mazur was granted 600,000 stock options and reports holdings of over 10 million common shares and various warrants and options.

Citius Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors and ratify its independent auditor.

Citius Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors and ratify its independent auditor, alongside detailed corporate governance and executive compensation disclosures.

Citius Pharmaceuticals is holding a special meeting on June 9, 2025, to vote on increasing the authorized number of shares and potentially adjourning the meeting for further proxy solicitation.

Citius Pharmaceuticals is holding a special meeting to request stockholder approval for an amendment to their Articles of Incorporation to increase the authorized number of shares, aiming to secure future funding and strategic flexibility.

Citius Pharmaceuticals has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Citius Pharmaceuticals is holding its annual meeting on March 10, 2025, to vote on key proposals including director elections, executive compensation, and increasing authorized shares.

Citius Pharmaceuticals, Inc. increased its beneficial ownership in Citius Oncology, Inc. to 77.9% following a registered direct offering.

Citius Pharmaceuticals, Inc.'s beneficial ownership in Citius Oncology, Inc. decreased to 79.1% following a registered direct offering by the subsidiary.

Citius Pharmaceuticals, Inc. maintains an 84.3% beneficial ownership in Citius Oncology, Inc. after Citius Oncology's recent public offering of common shares.

Citius Pharmaceuticals, Inc. filing details adjustments in beneficial ownership by CVI Investments, Inc. and Heights Capital Management, Inc., primarily related to warrant exercisability.

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a combined beneficial ownership of 9.9% in Citius Pharmaceuticals, Inc. common stock.

CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., have disclosed a 9.9% beneficial ownership stake in Citius Pharmaceuticals, Inc.